铁质中介的炎症促进了肺高血压
Felipe Kazmirczak1, Neal T Vogel2, Sasha Z Prisco2
1Minneapolis Heart Institute, MN (F.K.).
Circulation research
|October 18, 2024
概括
细胞死亡途径铁亡,通过代谢和炎症过程驱动肺动脉高血压 (PAH). 在临床前模型中,用Ferrostatin-1抑制铁生减轻了PAH的严重程度和相关炎症.
科学领域:
- 细胞生物学 细胞生物学
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 线粒体功能障碍会损害脂质代谢,导致脂质过氧化和铁亡,一种炎症性细胞死亡.
- 铁性促进补体激活和巨细胞的招募,有助于肺动脉高血压 (PAH) 的病原性.
- 在PAH中,肺动脉内皮细胞表现出促进铁亡的表型,有异位补体沉积和肺血管中的炎症性巨细胞.
研究的目的:
- 研究ferroptosis抑制对临床前肺动脉高血压 (PAH) 病原机制的影响.
- 评估调节铁亡对PAH肺血管细胞格局的影响.
- 在人类遗传研究中探索铁亡和肺高血压严重程度之间的关系.
主要方法:
- 用多组学 (RNA测序,蛋白学) 和生理分析来评估在临床前PAH模型中的ferroptosis抑制.
- 腺相关病毒1介导的乙基-CoA合成酶长链家族成员4 (ACSL4) 的表达被用于研究铁灭症诱导.
- 在范德比尔特BioVU存储库中进行了使用单核酸多态化在铁灭基因中的遗传关联研究.
主要成果:
- 铁素-1,一种铁灭抑制剂,在单克罗他林诱导的老鼠模型中减轻了PAH的严重程度.
- RNA测序和蛋白质组学证实了铁亡与PAH严重性的关联,并显示Ferrostatin-1抑制了补体激活和促炎细胞因子.
- 费罗斯塔丁-1治疗逆转了PAH模型中的内皮细胞,光滑肌肉和巨细胞群和基因表达的变化.
- 实验室研究表明,与ferroptotic细胞损伤相关的分子模式促进了光滑肌肉细胞的增殖和单细胞炎症.
- 在大鼠中,ACSL4诱导促进了炎症PAH表型.
- 人类遗传分析揭示了铁灭菌基因多态和PAH严重程度之间的潜在联系.
结论:
- 铁绝症通过肺血管中的代谢和炎症途径显著促进肺动脉高血压 (PAH).
- 抑制铁亡是一种潜在的治疗策略,可以缓解PAH进展及其相关的炎症并发症.
更多相关视频
相关概念视频
01:16Necrosis
4.4K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K
01:30Pulmonary Hypertension: Classification and Pathogenesis
151
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
151
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
177
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
177